Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.76 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.76 |
| ▸ | RELA | Q04206 | 3/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.76 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383541 | 1.00 | MEN1 (0.76) | MEN1KMT2ANFKB1NFKB2RELA | |
| SCHEMBL31232994 | 0.91 | MEN1 (0.72) | MEN1KMT2ANFKB1NFKB2RELA | |
| SCHEMBL15218642 | 0.91 | MEN1 (0.72) | MEN1KMT2ANFKB1NFKB2RELA | |
| SCHEMBL17616945 | 0.88 | MEN1 (0.76) | MEN1KMT2ANFKB1NFKB2RELA | |
| SCHEMBL30382794 | 0.88 | MEN1 (0.76) | MEN1KMT2ANFKB1NFKB2RELA | |
| Butein SCHEMBL25202104 | 0.86 | KMT2A (1.00) | MEN1KMT2ANFKB1NFKB2RELA | |
| Butein SCHEMBL139243 | 0.86 | KMT2A (1.00) | MEN1KMT2ANFKB1NFKB2RELA | |
| Butein SCHEMBL243646 | 0.86 | KMT2A (1.00) | MEN1KMT2ANFKB1NFKB2RELA | |
| Butein SCHEMBL243647 | 0.86 | KMT2A (1.00) | MEN1KMT2ANFKB1NFKB2RELA | |
| Butein SCHEMBL29724857 | 0.86 | KMT2A (1.00) | MEN1KMT2ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20150366206-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | HEINRICH HEINE UNIVERSITÄT DÜSSELDORF (DE) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366206-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | PC, CPS1, ME1 | MEN1 2751/4885KMT2A 2285/4885NFKB1 3209/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MEN1 3367/4885KMT2A 2792/4885NFKB1 1669/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MEN1 2457/4885KMT2A 3188/4885NFKB1 2437/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MEN1 2457/4885KMT2A 3188/4885NFKB1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.